Top

Published in:

01-07-2014 | Research Article

N-Acetyltransferase 2 status and gastric cancer risk: a meta-analysis

Authors: Jian Yu, Yue Deng, Jian-Ping Chen

Published in: Tumor Biology | Issue 7/2014

Abstract

Case–control studies on the association between N-acetyltransferase 2 (NAT2) genotype and gastric cancer have provided either controversial or inconclusive results. In order to clarify the influence of NAT2 acetylation status on gastric cancer risk, a meta-analysis was undertaken. The primary outcome measure was the odds ratio (OR) for the risk of gastric cancer associated with the NAT2 genotype. The overall result showed that there was no statistically significant association between NAT2 status and gastric cancer risk (slow acetylation vs. rapid acetylation, OR = 1.10, 95 % confidence interval (CI) 0.97–1.25, p = 0.12). In the analysis stratified by East Asian ethnicity, a significant association was found between gastric cancer and the NAT2 genotype (slow acetylation vs. rapid acetylation, OR = 1.33, 95 % CI 1.11–1.59, p = 0.002). Our pooled data suggest that the NAT2 acetylation status has an effect on the risk of gastric cancer among East Asian populations.

Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMed

Zhang W, Huang J, Peng G, Ding Q, Chen J, Hua Y, et al. Null genotype of glutathione S-transferase T1 contributes to increased risk of gastric cancer in Asian population. Tumour Biol. 2013;34(3):1461–6.CrossRefPubMed

Ma Y, Wei X, Han G, Xue M, Li G, Li Y. Glutathione S-transferase P1 Ile105Val polymorphism contributes to increased risk of gastric cancer in East Asians. Tumour Biol. 2013;34(3):1737–42.CrossRefPubMed

Zou TH, Wang ZH, Fang JY. Positive association between Toll-like receptor 4 gene +896A/G polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Tumour Biol. 2013;34(4):2441–50.CrossRefPubMed

Kadlubar FF, Butler MA, Kaderlik KR, Chou HC, Lang NP. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect. 1992;98:69–74.PubMedCentralCrossRefPubMed

Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res. 1999;436(3):227–61.CrossRefPubMed

Oda Y, Kobayashi M, Ooi A, Muroishi Y, Nakanishi I. Genotypes of glutathione S-transferase M1 and N-acetyltransferase 2 in Japanese patients with gastric cancer. Gastric Cancer. 1999;2(3):158–64.CrossRefPubMed

Katoh T, Boissy R, Nagata N, Kitagawa K, Kuroda Y, Itoh H, et al. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer. 2000;85(1):46–9.CrossRefPubMed

Ladero JM, Agúndez JA, Olivera M, Lozano L, Rodríguez-Lescure A, Diaz-Rubio M, et al. N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. Eur J Clin Pharmacol. 2002;58(2):115–8.CrossRefPubMed

10.

Shen X, Zhang J, Yan Y, Yang Y, Fu G, Pu Y. Analysis and estimates of the attributable risk for environmental and genetic risk factors in gastric cancer in a Chinese population. J Toxicol Environ Health A. 2009;72(11–12):759–66.CrossRefPubMed

11.

Boissy RJ, Watson MA, Umbach DM, Deakin M, Elder J, Strange RC, et al. A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma. Int J Cancer. 2000;87(4):507–11.CrossRefPubMed

12.

Al-Moundhri MS, Al-Kindi M, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Madhani A, et al. NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations. World J Gastroenterol. 2007;13(19):2697–702.PubMedCentralCrossRefPubMed

13.

Boccia S, Sayed-Tabatabaei FA, Persiani R, Gianfagna F, Rausei S, Arzani D, et al. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case–control study in an Italian population. BMC Cancer. 2007;7:206.PubMedCentralCrossRefPubMed

14.

Hosseini H, Dovranehgard F, Arveysi S, Galehdari H, Masjedizadeh A, Shanaki M. No association between N-acetyltransferase 2 (NAT2) and risk of diffuse type of gastric cancer. Toxicol Lett. 2009;189:S138.CrossRef

15.

Hong SH, Kim JW, Kim HG, Park IK, Ryoo JW, Lee CH, et al. Glutathione S-transferases (GSTM1, GSTT1 and GSTP1) and N-acetyltransferase 2 polymorphisms and the risk of gastric cancer. J Prev Med Public Health. 2006;39(2):135–40.PubMed

16.

Kobayashi M, Otani T, Iwasaki M, Natsukawa S, Shaura K, Koizumi Y, et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case–control study in Japan. Gastric Cancer. 2009;12(4):198–205.CrossRefPubMed

17.

Lan Q, Rothman N, Chow WH, Lissowska J, Doll MA, Xiao GH, et al. No apparent association between NAT1 and NAT2 genotypes and risk of stomach cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(4):384–6.PubMed

18.

Malik MA, Upadhyay R, Modi DR, Zargar SA, Mittal B. Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir Valley. Arch Med Res. 2009;40(5):416–23.CrossRefPubMed

19.

Park JS, Kim H, Song YJ, Yun HY, Kang JW, Kim YD, et al. Effects of environmental carcinogens and genetic polymorphisms of CYP2E1 and NAT2 on gastric carcinogenesis. J Korean Surg Soc. 2000;59(4):488–99.

20.

Suzuki S, Muroishi Y, Nakanishi I, Oda Y. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol. 2004;39(3):220–30.CrossRefPubMed

21.

Yun HY, Kim JK, Song YJ, Park JS, Lee CH, Nam HM, et al. Effect of the genetic polymorphism of N-acetyltransferase 2 and diet on the carcinogenesis of gastric cancer in Koreans. J Korean Surg Soc. 2003;64(6):459–65.

22.

Zhang J, Shen XB, Pu YP. Relationship between N-acetyltransferases genetic polymorphisms and susceptibility to stomach cancer. Chin J Public Health. 2006;22(5):576–7.

23.

Zhang YW, Eom SY, Kim YD, Song YJ, Yun HY, Park JS, et al. Effects of dietary factors and the NAT2 acetylator status on gastric cancer in Koreans. Int J Cancer. 2009;125(1):139–45.PubMedCentralCrossRefPubMed

24.

Zhong X, Hui C, Xiao-Ling W, Yan L, Na L. NAT2 polymorphism and gastric cancer susceptibility: a meta-analysis. Arch Med Res. 2010;41(4):275–80.CrossRefPubMed

25.

Boccia S, La Torre G, Gianfagna F, Ricciardi G. N-Acetyltransferase 2 status and gastric cancer risk: a preliminary meta-analysis. Ital J Public Health. 2005;2(1):53–7.

Title: N-Acetyltransferase 2 status and gastric cancer risk: a meta-analysis
Authors: Jian Yu
Yue Deng
Jian-Ping Chen
Publication date: 01-07-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1847-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2014

Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer

PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation

Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients

High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy

Expression of basic fibroblast growth factor, CD31, and α-smooth muscle actin and esophageal cancer recurrence after definitive chemoradiation

May increased CA125 in borderline ovarian tumor be indicative of a poor prognosis? A case report

Keynote webinar | Spotlight on antibody–drug conjugates in cancer